"The phase I study combining sorafenib with SBRT shown today highlights the exciting promise of greater efficacy, but with caution due to potential toxicity," she said. "It also reflects the challenging research necessary to optimize such novel approaches for clinical use."
Dr. Park was comoderator at a briefing where the data were presented but was not involved in the study.
Dr. Brade disclosed a research grant from Bayer. Dr. Park disclosed having an investment interest in Oncosynergy, a biotechnology company.